Manuscripts (34 of 557)

Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Ni Gao, Helen A. Dakin, Rury R. Holman, Lee Ling Lim, José Leal, Philip Clarke
PharmacoEconomics 2024;42:1017-1028. Published:Sep-2024. Epub:26-Jun-2024. PMID:38922488. doi:10.1007/s40273-024-01398-4

Time-Dependent Event Accumulation in a Cardiovascular Outcome Trial of Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease
M. Angelyn Bethel, Harald Sourij, Susanna R. Stevens, Karen Hannan, Yuliya Lokhnygina, Amanda I. Adler, Eric D. Peterson, Rury R. Holman, Renato D. Lopes
Cardiovasc Diabetol. 2023;22:72. Published:28-Mar-2023. PMID:36978066. doi:10.1186/s12933-023-01802-x

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
Jessica A Regan, Lauren K Truby, Usman A Tahir, Daniel H Katz, Maggie Nguyen, Lydia Coulter Kwee, Shuliang Deng, James G Wilson, Robert J Mentz, William E Kraus, Adrian F Hernandez, Robert E Gerszten, Eric D Peterson, Rury R Holman, Svati H Shah
Sci Rep. 2022;12:20072. Published:Nov-2022. PMID:36418363. doi:10.1038/s41598-022-24226-1

Development and Validation of a Model to Predict Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
Susanna R. Stevens, Matthew W. Segar, Ambarish Pandey, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Eberhard Standl, Eric D. Peterson, Rury R. Holman
Cardiovasc Diabetol. 2022;21:166. Published:27-Aug-2022. PMID:36030198. doi:10.1186/s12933-022-01603-8

Validation of the WATCH- DM and TRS- HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis
Matthew W. Segar, Kershaw V. Patel, Anne S. Hellkamp, Muthiah Vaduganathan, Yuliya Lokhnygina, Jennifer B. Green, Siu-Hin Wan, Ahmed A. Kolkaila, Rury R. Holman, Eric D. Peterson, Vaishnavi Kannan, Duwayne L. Willett, Darren K. McGuire and Ambarish Pandey
J Am Heart Assoc. 2022;11:e024094. Published:07-Jun-2022. Epub:03-Jun-2022. PMID:35656988. doi:10.1161/JAHA.121.024094

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
Abhinav Sharma, Yinggan Zheng, Justin A Ezekowitz, Cynthia M Westerhout, Jacob A Udell, Shaun G Goodman, Paul W Armstrong, John B Buse, Jennifer B Green, Robert G Josse, Keith D Kaufman, Darren K McGuire, Giuseppe Ambrosio, Lee-Ming Chuang, Renato D Lopes, Eric D Peterson, Rury R Holman
Diabetes Care 2022;45:04-212. Published:Jan-2022. Epub:29-Oct-2021. PMID:34716214. doi:10.2337/dc20-2806

Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
Finlay A McAlister, Yinggan Zheng, Cynthia M Westerhout, John B Buse, Eberhard Standl, Darren K McGuire, Frans Van de Werf, Jennifer B Green, Paul W Armstrong, Rury R Holman, TECOS Study Group
Eur J Heart Fail. 2020;22:2026-2034. Published:Nov-2020. Epub:04-Jul-2020. PMID:32621557. doi:10.1002/ejhf.1958

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Laurie L. Baggio, Elodie M. Varin, Jacqueline A. Koehler, Yuliya Lokhnygina, Susanna Stevens, Rury R. Holman, and Daniel J. Drucker
Nat Commun. 2020;11:3766. Published:28-Jul-2020. PMID:32724076. doi:10.1038/s41467-020-17556-z

Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
Gaetano M. De Ferrari, Susanna R. Stevens, Giuseppe Ambrosio, Sergio Leonardi, Darren K. McGuire, Paul W. Armstrong, Jennifer B. Green, Malgorzata Wamil, Rury R. Holman, Eric D. Peterson; on behalf of the TECOS Study Group
Am Heart J 2020;220:82-88. Published:Feb-2020. Epub:04-Dec-2019. PMID:31790905. doi:10.1016/j.ahj.2019.11.005

Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study Group
Am Heart J 2020;219:47-57. Published:Jan-2020. Epub:20-Oct-2019. PMID:31707324. doi:10.1016/j.ahj.2019.09.016

Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
Jay S. Shavadia, Yinggan Zheng, Jennifer B. Green, Paul W. Armstrong, Cynthia M. Westerhout, Darren K. McGuire, Jan H. Cornel, Rury R. Holman, Eric D. Peterson
Am Heart J 2019;218:92-99. Published:Dec-2019. Epub:20-Oct-2019. PMID:31715435. doi:10.1016/j.ahj.2019.09.013

International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS
Ankeet S. Bhatt, Nancy Luo, Nicole Solomon, Neha J. Pagidipati, Giuseppe Ambrosio, Jennifer B. Green, Darren K. McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D. Lopes, Harvey D. White, Rury R. Holman, Eric D. Peterson, Robert J. Mentz, on behalf of the TECOS Study Group
Am Heart J 2019;218:57-65. Published:Dec-2019. Epub:28-Aug-2019. PMID:31707329. doi:10.1016/j.ahj.2019.08.016

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman
Cardiovasc Diabetol 2019;18:116. Published:03-Sep-2019. PMID:31481069. doi:10.1186/s12933-019-0921-2

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes
Patrícia O. Guimarães, Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, Renato D. Lopes
Int J Cardiol. 2019;289:58-62. Published:15-Aug-2019. Epub:30-Apr-2019. PMID:31079973. doi:10.1016/j.ijcard.2019.04.085

Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163
Eberhard Standl, Jennifer B. Green, Rury R. Holman
Diabetes Care 2019;42:e95. Published:Jun-2019. PMID:31110121. doi:10.2337/dc18-2597

Progression of glucose-lowering diabetes therapy in TECOS
M. Angelyn Bethel, Samuel S. Engel, Susanna R. Stevens, Yuliya Lokhnygina, Jie Ding, Robert G. Josse, Michael Alvarsson, Irene Hramiak, Jennifer B. Green, Eric D. Peterson, Rury R. Holman
Endocrinol Diab Metab 2019;2:e00053. Published:13-Jan-2019. Epub:23-Dec-2018. PMID:30815579. doi:10.1002/edm2.53

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA, Coleman RL, Agbaje OF, Gray A, Holman RR, Bethel MA
J Diabetes Complications 2019;33:69-74. Published:Jan-2019. Epub:10-Oct-2018. PMID:30361000. doi:10.1016/j.jdiacomp.2018.09.017

Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Reed SD, Li Y, Leal J, Graham F, Radican L, Adler A, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group
Diabetes Obes Metab 2018;20:1732-1739. Published:Jul-2018. Epub:23-Mar-2018. PMID:29573215. doi:10.1111/dom.13292

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
Eberhard Standl, Susanna R. Stevens, Paul W. Armstrong, John B. Buse, Juliana C.N. Chan, Jennifer B. Green, John M. Lachin, Andre Scheen, Florence Travert, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2018;41:596-603. Published:Mar-2018. Epub:08-Jan-2018. PMID:29311155. doi:10.2337/dc17-1778

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman and M. A. Bethel
Diabet Med. 2018;35:72-77. Published:Jan-2018. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS
Alfredsson J, Green JB, Stevens SR, Reed SD, Hramiak I, White H, Armstrong PW, Bethel MA, Engel SS, McGuire DK, Van de Werf F, Peterson ED, Holman RR, on Behalf of the TECOS Study Group
Diabetes Obes Metab. 2018;20:2379-2388. Epub:19-Jun-2018. PMID:29923323. doi:10.1111/dom.13377

Effect of race on the glycaemic response to sitagliptin. Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Davis TME, Mulder H, Lokhnygina Y, Standl E, Aschner P, Chuang LM, Grado CR, Peterson ED, Holman RR
Diabetes, Obesity and Metabolism 2018;20:1427-1434. Epub:06-Feb-2018. PMID:29405540. doi:10.1111/dom.13242

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Abhinav Sharma, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, John M. Lachin, Frans Van de Werf, Paul W. Armstrong, Keith D. Kaufman, Eberhard Standl, Juliana C.N. Chan, Larry A. Distiller, Russell Scott, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2017;40:1763-1770. Published:Dec-2017. Epub:06-Oct-2017. PMID:28986504. doi:10.2337/dc17-1091

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED
Hypertension 2017;70:907-914. Published:Nov-2017. Epub:28-Aug-2017. PMID:28847886. doi:10.1161/HYPERTENSIONAHA.117.09482

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS
Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group
Diabetes Obes Metab. 2017;19:1587–1593. Published:Nov-2017. Epub:22-Apr-2017. PMID:28432745. doi:10.1111/dom.12983

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International 2 Insights from the TECOS Trial
Neha J. Pagidipati, Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, Darren K. McGuire, Yuliya Lokhnygina, Jan H. Cornel, Sigrun Halvorsen, Timo E. Strandberg, Tuncay Delibasi, Rury R. Holman, Eric D. Peterson, On behalf of the TECOS Study Group
Circulation 2017;136:1193–1203. Published:26-Sep-2017. Epub:16-Jun-2017. PMID:28626088. doi:10.1161/CIRCULATIONAHA.117.027252

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, Rury R. Holman, for the TECOS Study Group
Diabetes Care 2017;40:494–501. Published:Apr-2017. Epub:05-Jan-2017. PMID:28057693. doi:10.2337/dc16-1135

Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group.
Diabetes Care 2017;40:164-170. Published:Feb-2017. Epub:14-Sep-2016. PMID:27630212. doi:10.2337/dc15-2780

Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group
Diabetes Obes Metab 2017;19:78-86.. Published:Jan-2017. Epub:08-Sep-2016. PMID:27607571. doi:10.1111/dom.12786

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel, George L. Bakris, Susanna R. Stevens, Michael Alvarsson, Willem A. Bax, Lee-Ming Chuang, Samuel S. Engel, Renato D. Lopes, Darren K. McGuire, Axel Riefflin, Helena Wachslicht Rodbard, Isaac Sinay, Tsvetalina Tankova, Julio Wainstein, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2016;39:2304-2310. Published:Dec-2016. Epub:14-Oct-2016. PMID:27742728. doi:10.2337/dc16-1415

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
Darren K. McGuire, Frans Van deWerf, PaulW. Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B. Green, M. Angelyn Bethel, Jan H. Cornel, Renato D. Lopes, Sigrun Halvorsen, Giuseppe Ambrosio, John B. Buse, Robert G. Josse, John M. Lachin, Michael J. Pencina, Jyotsna Garg, Yuliya Lokhnygina, Rury R. Holman, Eric D. Peterson, for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group
JAMA Cardiology 2016;1:126-135. Published:May-2016. Epub:13-Apr-2016. PMID:27437883. doi:10.1001/jamacardio.2016.0103

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
N Engl J Med 2015;373:232-242. Published:16-Jul-2015. Epub:08-Jun-2015. PMID:26052984. doi:10.1056/NEJMoa1501352
Erratum in :
N Engl J Med 201;373:586, Print:06-Aug-2015, Epub:16-Jul-2015, PMID:26182233, doi:10.1056/NEJMx150029

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M. A. Bethel, J. B. Green, J.Milton, A.Tajar, S.S.Engel, R.M.Califf, R.R.Holman on behalf of the TECOS Executive Committee
Diabetes, Obesity and Metabolism 2015;17:395-402. Published:Apr-2015. Epub:13-Feb-2015. PMID:25600421. doi:10.1111/dom.12441

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman
American Heart Journal 2013;166:983-989.e7. Published:Dec-2013. Epub:23-Oct-2013. PMID:24268212. doi:10.1016/j.ahj.2013.09.003